Evidence map›Paper›PMID 40684402›Full record

ArticleNeurology and therapy2025

Clinical Performance of the Elecsys CSF pTau

Ruben Smith, Leslie Shaw, Sebastian Palmqvist, Niklas Mattsson-Carlgren, Gregory Klein, Matteo Tonietto, Alzheimer’s Disease Neuroimaging Initiative, Clara Quijano-Rubio, Christopher M Rank, Myrto Andreadou and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. The value of timely treatment with anti-amyloid therapy for Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ruben SmithClinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden.ORCID http://orcid.org/0000-0001-7147-0112
Leslie ShawCenter for Neurodegenerative Research, Perelman School of Medicine, Department of Pathology and Laboratory Medicine and the PENN Alzheimer's Disease Research Center, University of Pennsylvania, Philadelphia, PA, USA.
Sebastian PalmqvistClinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden.ORCID http://orcid.org/0000-0002-9267-1930
Niklas Mattsson-CarlgrenClinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden.
Gregory KleinResearch and Early Development (pRED), F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Matteo ToniettoResearch and Early Development (pRED), F. Hoffmann-La Roche Ltd, Basel, Switzerland.ORCID http://orcid.org/0000-0001-9591-5710
Alzheimer’s Disease Neuroimaging Initiative
Clara Quijano-RubioRoche Diagnostics International Ltd, Forrenstrasse 2, 6343, Rotkreuz, Switzerland. clara.quijano_rubio@roche.com.ORCID http://orcid.org/0000-0001-9050-3282
Christopher M RankRoche Diagnostics GmbH, Penzberg, Germany.
Myrto AndreadouRoche Diagnostics International Ltd, Forrenstrasse 2, 6343, Rotkreuz, Switzerland.ORCID http://orcid.org/0000-0001-6757-4664
Samantha C BurnhamEli Lilly and Company, Indianapolis, IN, USA.
Erik StomrudClinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden.ORCID http://orcid.org/0000-0002-0841-5580

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAmyloid- and tau-positron emission tomography (PET) are promising modalities for detecting pathological changes associated with Alzheimer's disease (AD); however, their application is limited. Although the use of cerebrospinal fluid (CSF) biomarkers as alternatives to amyloid-PET and tau-PET has been explored, no in vitro diagnostic-approved or commercial CSF biomarker assays are currently available for detecting tau pathology in clinical practice.

methodsIn this study, we determined and validated the optimal cutoff value for the ratio of tau phosphorylated at a threonine residue at position 181 (pTau

resultsIn the first part of this analysis (ADNI-2/3 pre-analytics), a CSF pTau

conclusionThe Elecsys CSF pTau

Indexed as

Alzheimer’s diseaseCerebrospinal fluidClinical performanceCutoff determination and validationElecsys immunoassaysPositron emission tomographypTau181/Aβ42Routine-use pre-analytical handlingTau pathology

Identifiers

PMID40684402
PMCPMC12450182

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.